Depemokimab for pulmonary disease, chronic obstructive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 May 2025: Trial registered, NCT06961214
  2. 23 Jun 2025: Trial started, NCT06961214

The trials

NCT06961214: Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

State
Under way
Phase
Phase 3
People
961 planned
Started
23 Jun 2025
Primary completion
13 Dec 2028
Arms
Depemokimab
Results
None posted
  1. 7 May 2025: Trial registered
  2. 23 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.